[{"articleID":"","componentNumber":1,"slidePath":"//_2","rawSlides":"<!DOCTYPE HTML PUBLIC \"-//W3C//DTD HTML 4.0 Transitional//EN\">\r\n<html lang=\"en\">\r\n<head><meta http-equiv=\"Content-Type\" content=\"text/html; charset=\">\r\n<title>Handoff Notes and Reminders\r\n</title>\r\n</head>\r\n\r\n<body >\r\n\r\n\r\n<table border=\"1\" cellpadding=\"3\" cellspacing=\"1\">\r\n<tr valign=\"top\">\r\n<td><p><img height=\"51\" width=\"199\" src=\"Cardio%20SPT%20%20Kakkar%20239054-29%20v400.jpg\" \talt=\"Cardio%20SPT%20%20Kakkar%20239054-29%20v400.jpg\" border=\"0\" ></p>\r\n</td>\r\n<td><p><strong>Production Ticket</strong></p>\r\n</td>\r\n</tr>\r\n\r\n</table>\r\n<p></p>\r\n\r\n\r\n<table border=\"1\" cellpadding=\"3\" cellspacing=\"1\">\r\n<tr valign=\"top\">\r\n<td><p><strong>Who?</strong></p>\r\n</td>\r\n<td><p><strong>When?</strong></p>\r\n</td>\r\n<td><p><strong>What?</strong></p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>M Felton</p>\r\n</td>\r\n<td><p>5/22/18</p>\r\n</td>\r\n<td><p>initiate</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>C Padbury</p>\r\n</td>\r\n<td><p>8/1</p>\r\n</td>\r\n<td><p>Content</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>J Habib</p>\r\n</td>\r\n<td><p>8/15/18</p>\r\n</td>\r\n<td><p>Outcomes Review</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>D Frassetto</p>\r\n</td>\r\n<td><p>8/23/18</p>\r\n</td>\r\n<td><p>Copyedit</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>N Zawahir</p>\r\n</td>\r\n<td><p>8/30/18</p>\r\n</td>\r\n<td><p>CME Review</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>E Casey</p>\r\n</td>\r\n<td><p>8/30/18</p>\r\n</td>\r\n<td><p>Registered for ABIM MOC</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td>&nbsp;</td>\r\n<td>&nbsp;</td>\r\n<td>&nbsp;</td>\r\n</tr>\r\n\r\n</table>\r\n<p>Click <strong>+</strong> to add another table row</p>\r\n\r\n<p>&#953; = additional instructions available when you hover cursor over; <strong>Bold text</strong> = questions to be answered</p>\r\n<h1>\r\n<a name=\"HandoffNotes\"></a><a name=\"Heading31\"></a><strong>Handoff Notes and Reminders</strong></h1>\r\n\r\n\r\n<table border=\"1\" cellpadding=\"3\" cellspacing=\"1\">\r\n<tr valign=\"top\">\r\n<td><p><strong>To Scientific Directors</strong></p>\r\n</td>\r\n<td>&nbsp;</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>To Copyeditors</strong></p>\r\n</td>\r\n<td>&nbsp;</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>To Production/Studio &#953;</strong></p>\r\n</td>\r\n<td>&nbsp;</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>To CME Department</strong></p>\r\n</td>\r\n<td>&nbsp;</td>\r\n</tr>\r\n\r\n</table>\r\n<h1>\r\n<a name=\"Heading40\"></a><strong>General Information</strong></h1>\r\n\r\n\r\n<table border=\"1\" cellpadding=\"3\" cellspacing=\"1\">\r\n<tr valign=\"top\">\r\n<td><p><strong>Activity SF#(s):</strong></p>\r\n</td>\r\n<td><p>239054.29</p>\r\n</td>\r\n<td><p><strong>Related SF#s &#953;:</strong></p>\r\n</td>\r\n<td>&nbsp;</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Supporter(s):</strong></p>\r\n</td>\r\n<td><p>Bayer AG</p>\r\n</td>\r\n<td><p><strong>Partner (s):</strong></p>\r\n</td>\r\n<td>&nbsp;</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Product type:</strong></p>\r\n</td>\r\n<td><p>Spotlight</p>\r\n</td>\r\n<td><p><strong>If live event, enter date:</strong></p>\r\n</td>\r\n<td><p>(Click to enter date...)</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td>&nbsp;</td>\r\n<td>&nbsp;</td>\r\n<td><p><strong>IME program?</strong></p>\r\n</td>\r\n<td><p>&#9746; No   &#9744; Yes</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Outcomes Study included? &#953;</strong></p>\r\n</td>\r\n<td><p>&#9744; No</p>\r\n</td>\r\n<td><p>&#9746; Yes; <strong>measurement focus:</strong> </p>\r\n</td>\r\n<td><p>&#9746; Competence     &#9744; Performance    &#9744;Patient Outcomes</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Geotargets &#953;</strong></p>\r\n</td>\r\n<td><p><strong>1:</strong> Global</p>\r\n</td>\r\n<td><p><strong>2:</strong> (Choose a geotarget...)</p>\r\n</td>\r\n<td><p><strong>3:</strong> (Choose a geotarget...)</p>\r\n</td>\r\n<td><p><strong>4:</strong> (Choose a geotarget...)</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Select one supporter attribution:</strong></p>\r\n\r\n<p>&#9746; One Supporter</p>\r\n\r\n<p>&#9744; Multi-Support</p>\r\n\r\n<p>&#9744; Medscape-supported activity: Developed and funded by Medscape</p>\r\n</td>\r\n</tr>\r\n\r\n</table>\r\n\r\n\r\n<table border=\"1\" cellpadding=\"3\" cellspacing=\"1\">\r\n<tr valign=\"top\">\r\n<td><p><strong>Type of badge:</strong></p>\r\n</td>\r\n<td><p>&#9746; Text only</p>\r\n</td>\r\n<td><p>&#9744; Supporter logo</p>\r\n</td>\r\n<td>&nbsp;</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>Paste badge(s) here: <img height=\"69\" width=\"297\" src=\"Cardio%20SPT%20%20Kakkar%20239054-29%20v401.jpg\" \talt=\"C:\\Users\\mchevry\\Box Sync\\Documents\\US Supporter Badges\\Bayer AG.gif\" border=\"0\" ></p>\r\n</td>\r\n</tr>\r\n\r\n</table>\r\n<h1>\r\n<a name=\"Heading75\"></a><strong>Course/CME Details</strong></h1>\r\n\r\n\r\n<table border=\"1\" cellpadding=\"3\" cellspacing=\"1\">\r\n<tr valign=\"top\">\r\n<td><p><strong>Title: &#953;</strong></p>\r\n</td>\r\n<td><p>Cancer&#8208;Associated Thrombosis: Emerging Concepts and Paradigms</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Teaser: &#953;</strong></p>\r\n</td>\r\n<td><p>Drs Kakkar, Khorana, and Weitz discuss the challenge of identifying and treating patients with cancer at risk for VTE.</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Faculty/Author(s) Byline(s): &#953;</strong></p>\r\n</td>\r\n<td><p>Lord Ajay K. Kakkar, MD, PhD, FRCS, FRCP; Alok A. Khorana, MD; Jeffrey I. Weitz, MD, FRCP</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Indicate thumbnail URL &#953;:</strong></p>\r\n</td>\r\n<td>&nbsp;</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Target Audience:</strong></p>\r\n</td>\r\n<td><p>This activity is intended for cardiologists, hematologists/oncologists, and other healthcare professionals who treat patients with cancer.</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Goal Statement: </strong></p>\r\n</td>\r\n<td><p>The goal of this activity is to provide an update on new treatment strategies for patients with cancer at risk for thromboembolism.</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Peer review required?</strong></p>\r\n</td>\r\n<td><p>Yes</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Educational Design &#953;</strong></p>\r\n</td>\r\n<td><p>&#9746; Competence &#953;</p>\r\n</td>\r\n<td><p>&#9744; Performance &#953;</p>\r\n</td>\r\n<td><p>&#9744; Patient Outcomes &#953;</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Core Competencies &#953;</strong></p>\r\n</td>\r\n<td><p>&#9744; Patient care and procedural skills</p>\r\n</td>\r\n<td><p>&#9746; Medical knowledge</p>\r\n</td>\r\n<td><p>&#9744; Practice-based learning and improvement </p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td>&nbsp;</td>\r\n<td><p>&#9744; Interpersonal &amp; communication skills</p>\r\n</td>\r\n<td><p>&#9744; Professionalism</p>\r\n</td>\r\n<td><p>&#9744; Systems-based practice</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>IPCE Competencies &#953;</strong></p>\r\n</td>\r\n<td><p>&#9744; Interprofessional Education (IPCE)</p>\r\n</td>\r\n<td><p>&#9744; Roles and Responsibilities</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td>&nbsp;</td>\r\n<td><p>&#9744; Interprofessional Communication</p>\r\n</td>\r\n<td><p>&#9744; Teamwork &#953;</p>\r\n</td>\r\n<td><p>&#9744; Values and Ethics</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Activity Length &#953;:</strong></p>\r\n</td>\r\n<td><p>27 min</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Credits Available &#953;:</strong></p>\r\n\r\n<p>&#9746;<strong> Medscape Joint Accreditation Statement </strong></p>\r\n\r\n<p>Direct Provider:</p>\r\n\r\n<p>In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.</p>\r\n\r\n<p><img height=\"79\" width=\"124\" src=\"Cardio%20SPT%20%20Kakkar%20239054-29%20v402.jpg\" \talt=\"C:\\Users\\mchevry\\Box Sync\\Documents\\US Supporter Badges\\Bayer AG.gif\" border=\"0\" ></p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>&#9746; <strong>ACCME:</strong> 0.50 AMA PRA Category 1&#8482; Credit:</p>\r\n\r\n<p>For Physicians</p>\r\n\r\n<p>Medscape, LLC designates this enduring material for a maximum of 0.50 <strong><em>AMA PRA Category 1 Credit(s)&#8482;</em></strong>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>&#9744; <strong>ANCC:</strong> (Select credit hours...) contact hours (Select credit hours...) contact hours are in the area of pharmacology)</p>\r\n\r\n<p>(Select...)</p>\r\n\r\n<p>&#9746; <strong>ABIM MOC:  PARS Activity Identifier </strong>201126571</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>&#9744; <strong>ACPE:</strong> Knowledge-based (Select credit hours...) CEUs); Application-based (Select credit hours...) CEUs)</p>\r\n\r\n<p>(Select...)</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>&#9744; <strong>CPD:</strong> (Select...)</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>&#9744; <strong>OUS Options:</strong> (Select...)</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>&#9744; <strong>IME:</strong> (Select...)</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>&#9744; <strong>Other:</strong> (Click here to enter...)</p>\r\n</td>\r\n</tr>\r\n\r\n</table>\r\n<h1>\r\n\r\n\r\n<a name=\"Heading134\"></a><a name=\"Heading135\"></a><strong>Partner Details</strong></h1>\r\n\r\n\r\n<table border=\"1\" cellpadding=\"3\" cellspacing=\"1\">\r\n<tr valign=\"top\">\r\n<td><p><strong>Partner Statement:</strong></p>\r\n\r\n<p><strong>(edit standard statement if needed)</strong></p>\r\n</td>\r\n<td><p>Developed through a partnership between Medscape and enter partner. </p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Partner source marker required?</strong></p>\r\n</td>\r\n<td><p>&#9746; No</p>\r\n</td>\r\n<td><p>&#9744; Yes; enter partner abbreviation here: (Click here to enter...)</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Partner logo required?</strong></p>\r\n</td>\r\n<td><p>&#9746; No</p>\r\n</td>\r\n<td><p>&#9744; Yes; paste logo here:</p>\r\n</td>\r\n<td>&nbsp;</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Required passing score:</strong></p>\r\n</td>\r\n<td>&nbsp;</td>\r\n<td><p><strong>Evaluation required?</strong></p>\r\n</td>\r\n<td><p>&#9744; Yes     &#9744; No</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Copyright Statement:</strong></p>\r\n</td>\r\n<td><p>&#9746; &#169;2018 Medscape, LLC</p>\r\n</td>\r\n<td><p>&#9744; &#169;2018 WebMD Global, LLC</p>\r\n</td>\r\n<td><p>&#9744; &#169;2018 (Add Partner&#8217;s copyright statement...)</p>\r\n</td>\r\n</tr>\r\n\r\n</table>\r\n<h1>\r\n<a name=\"Heading154\"></a><strong>Collection Page Details</strong></h1>\r\n\r\n\r\n<table border=\"1\" cellpadding=\"3\" cellspacing=\"1\">\r\n<tr valign=\"top\">\r\n<td><p><strong>Is there a collection page?</strong></p>\r\n</td>\r\n<td><p>&#9744; No</p>\r\n</td>\r\n<td><p>&#9746; Yes; <strong>what type?</strong> Clinical Advances; <strong>provide name and URL:</strong> https://www.medscape.org/sites/advances/anticoagulation-thrombosis</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>\tIf &#8216;Clinical Advances,&#8217; which bucket does the content go in?</strong> VTE</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Add to other publications or pages?</strong></p>\r\n</td>\r\n<td><p>&#9744; No</p>\r\n</td>\r\n<td><p>&#9746; Yes; add <strong>URL(s) and bucket name(s) &#953;</strong>: https://www.medscape.org/oncology</p>\r\n</td>\r\n</tr>\r\n\r\n</table>\r\n<h1>\r\n<a name=\"Heading164\"></a><strong>Product-Specific Information and Add-ons</strong></h1>\r\n<p></p>\r\n\r\n\r\n<table border=\"1\" cellpadding=\"3\" cellspacing=\"1\">\r\n<tr valign=\"top\">\r\n<td><p><strong>Is there an Outcomes study?</strong></p>\r\n</td>\r\n<td><p>Linked Learning Assessment (Medscape)</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Is there a second Outcomes study?</strong></p>\r\n</td>\r\n<td><p>No</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Is there a Medscape Discuss or Discuss Lite?</strong></p>\r\n</td>\r\n<td><p>&#9746; No</p>\r\n</td>\r\n<td><p>&#9744; Medscape Discuss</p>\r\n</td>\r\n<td><p>&#9744; Medscape Discuss Lite</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Is there an associated HCP Perspective?</strong></p>\r\n</td>\r\n<td><p>&#9746; No</p>\r\n</td>\r\n<td><p>&#9744; Yes</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Is this program associated with a Patient Education Program or Destination Page?</strong></p>\r\n</td>\r\n<td><p>&#9746; No</p>\r\n</td>\r\n<td><p>&#9744; Yes</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p><strong>Provide server path for Prescription to Learn PDF:</strong></p>\r\n</td>\r\n<td>&nbsp;</td>\r\n</tr>\r\n\r\n</table>\r\n<h1>\r\n\r\n\r\n<a name=\"Heading182\"></a><a name=\"Heading183\"></a><strong>Learning Objectives and KMI Map</strong></h1>\r\n\r\n\r\n<table border=\"1\" cellpadding=\"3\" cellspacing=\"1\">\r\n<tr valign=\"top\">\r\n<td><p><strong>Upon completion of this activity, participants will:</strong></p>\r\n</td>\r\n<td><p><strong>Question type assessing this objective</strong></p>\r\n</td>\r\n<td><p>Question #</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>Have increased knowledge regarding the</p>\r\n</td>\r\n<td>&nbsp;</td>\r\n<td>&nbsp;</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>Latest data on use of non-vitamin K antagonist oral anticoagulants in the setting of cancer-associated thrombosis</p>\r\n</td>\r\n<td><p>Linked Pre-/Post-assessment</p>\r\n</td>\r\n<td><p>1,2</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td>&nbsp;</td>\r\n<td>&nbsp;</td>\r\n<td>&nbsp;</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>Have greater competence related to</p>\r\n</td>\r\n<td>&nbsp;</td>\r\n<td>&nbsp;</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>Risk assessment for venous thromboembolism (VTE) recurrence in patients with cancer</p>\r\n</td>\r\n<td><p>CME evaluation</p>\r\n</td>\r\n<td><p>1</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td><p>Strategies to tailor long-term VTE treatment strategies in patients with cancer</p>\r\n</td>\r\n<td><p>Linked Pre-/Post-assessment</p>\r\n</td>\r\n<td><p>3</p>\r\n</td>\r\n</tr>\r\n\r\n<tr valign=\"top\">\r\n<td>&nbsp;</td>\r\n<td>&nbsp;</td>\r\n<td>&nbsp;</td>\r\n</tr>\r\n\r\n</table>\r\n\r\n\r\n<h1>\r\n        <a name=\"Heading212\"></a>Questions (Evaluations, Assessments, and Posttests)</h1>\r\n        <p></p>\r\n        \r\n\r\n        <p>Question 1</p>\r\n        \r\n        <p>Question reporting priority: First</p>\r\n        \r\n        <p>Question must follow question # (optional):</p>\r\n        \r\n        <p>Question type: Pre/Post Assessment Question Pairs (LLA)</p>\r\n        \r\n        <p>Question Introduction (optional &#953;): The Hokusai VTE Cancer and SELECT-D trials were designed to test the use of edoxaban and rivaroxaban, respectively, in the <u>treatment</u> of cancer-associated thrombosis, after initial treatment with low-molecular-weight heparin (LMWH).</p>\r\n        \r\n        <p>Question: What doses of the drugs were chosen?</p>\r\n        \r\n        <p>Answer choices &#953;:</p>\r\n        \r\n        <p>&#8226;\tEdoxaban 30 mg daily; rivaroxaban 20 mg once daily </p>\r\n        \r\n        <p>&#8226;\tEdoxaban 60 mg daily; rivaroxaban 20 mg once daily</p>\r\n        \r\n        <p>&#8226;\tEdoxaban 30 mg daily; rivaroxaban 10 mg twice daily for 3 weeks, then 15 mg once daily</p>\r\n        \r\n        <p>&#8226;\tEdoxaban 60 mg daily; rivaroxaban 15 mg twice daily for 3 weeks, then 20 mg once daily</p>\r\n        \r\n        <p>Answer explanation: In the Hokusai VTE Cancer and SELECT-D trials the doses of the drugs chosen were edoxaban 60 mg daily; rivaroxaban 15 mg twice daily for 3 weeks, then 20 mg once daily.</p>\r\n        \r\n\r\n\r\n        <p>Question 2</p>\r\n        \r\n        <p>Question reporting priority: Second</p>\r\n        \r\n        <p>Question must follow question # 1:</p>\r\n        \r\n        <p>Question type: Pre/Post Assessment Question Pairs (LLA)</p>\r\n        \r\n        <p>Question Introduction (optional &#953;): The CASSINI and AVERT trials are designed to test the use of rivaroxaban and apixaban, respectively, in the <u>prevention</u> of cancer-associated thrombosis.</p>\r\n        \r\n        <p>Question 2: What doses of the drugs were chosen?</p>\r\n        \r\n        <p>Answer choices &#953;:</p>\r\n        \r\n        <p>&#8226;\tRivaroxaban 20 mg once daily; apixaban 5 mg twice daily</p>\r\n        \r\n        <p>&#8226;\tRivaroxaban 15 mg once daily; apixaban 5 mg twice daily</p>\r\n        \r\n        <p>&#8226;\tRivaroxaban 10 mg once daily; apixaban 2.5 mg twice daily</p>\r\n        \r\n        <p>&#8226;\tRivaroxaban 5 mg once daily; apixaban 2.5 mg twice daily</p>\r\n        \r\n        <p>Answer explanation: In the CASSINI and AVERT trials, doses of the drugs chosen were rivaroxaban 10 mg and apixaban 2.5 mg twice daily, respectively.</p>\r\n        \r\n\r\n\r\n        <p>Question 3</p>\r\n        \r\n        <p>Question reporting priority: Third</p>\r\n        \r\n        <p>Question must follow question # (optional):</p>\r\n        \r\n        <p>Question type: Pre/Post Assessment Question Pairs (LLA)</p>\r\n        \r\n        <p>Question Introduction (optional &#953;): In patients with newly diagnosed cancer who developed VTE, the Kaplan-Meier rate of persistence with LMWH was 37%.</p>\r\n        \r\n        <p>Question: What percentage of patients could be expected to remain on oral anticoagulation at 6 months? </p>\r\n        \r\n        <p>Answer choices &#953;:</p>\r\n        \r\n        <p>&#8226;\t40%</p>\r\n        \r\n        <p>&#8226;\t50%</p>\r\n        \r\n        <p>&#8226;\t60%</p>\r\n        \r\n        <p>&#8226;\t70%</p>\r\n        \r\n        <p>Answer explanation: A total of 2941 patients with newly diagnosed cancer who developed VTE and received anticoagulation in outpatient settings were identified. The Kaplan-Meier rate of persistence to both rivaroxaban and warfarin therapy at 6 months was 61%. </p>\r\n        \r\n\r\n\r\n        <p>Question 4</p>\r\n        \r\n        <p>Question reporting priority: Choose an item.</p>\r\n        \r\n        <p>Question must follow question # (optional):</p>\r\n        \r\n        <p>Question type: Pre/Post Assessment Question Pairs (LLA)</p>\r\n\r\n        <p>Choose a building block.</p>\r\n\r\n        <p>Question: How confident are you in treating patients with cancer who develop venous thromboembolism? (Select ranking from 1 [Not confident] to 5 [Very confident])</p>\r\n        \r\n        <p>Answer choices:</p>\r\n        \r\n        <p>&#8226;\t1 - Not confident</p>\r\n        \r\n        <p>&#8226;\t2</p>\r\n        \r\n        <p>&#8226;\t3</p>\r\n        \r\n        <p>&#8226;\t4</p>\r\n        \r\n        <p>&#8226;\t5 &#8211; Very confident</p>\r\n        \r\n\r\n\r\n        <p>Question 5 (demographic)</p>\r\n        \r\n        <p>Question must follow question # (optional):</p>\r\n        \r\n        <p>Choose a building block.</p>\r\n\r\n        <p>Show question in pre- or postassessment? Post assessment only</p>\r\n        \r\n        <p>Question: Please indicate your prior familiarity with the subject matter. What percentage of this program's content was new to you?</p>\r\n        \r\n        <p>&#8226;\t0%</p>\r\n        \r\n        <p>&#8226;\t1%-24%</p>\r\n        \r\n        <p>&#8226;\t25%-49%</p>\r\n        \r\n        <p>&#8226;\t50%-74%</p>\r\n        \r\n        <p>&#8226;\t75%-99%</p>\r\n        \r\n        <p>&#8226;\t100%</p>\r\n        \r\n        \r\n\r\n        <p>Question type: CME Posttest</p>\r\n        \r\n        <p>Question Introduction (optional &#953;): </p>\r\n        \r\n        <p>Question 1: Which of the following statements is true?</p>\r\n        \r\n        <p>Answer choices &#953;:</p>\r\n        \r\n        <p>&#8226;\tA woman with breast cancer would have the same risk of thrombosis as a woman with lung cancer</p>\r\n        \r\n        <p>&#8226;\tGastrointestinal (GI) cancers put patients at particularly high risk of thrombosis</p>\r\n        \r\n        <p>&#8226;\t A history of venous thromboembolism (VTE) does not predict a higher risk for VTE </p>\r\n        \r\n        <p>&#8226;\tMen are more at risk for cancer-associated thrombosis than women</p>\r\n        \r\n        <p>&#8226;\tAnswer explanation: Patients with GI cancer, particularly upper GI cancers, esophageal cancer, gastric cancer, and cancer within the lumen of the GI tract, are at a particularly high risk of thrombosis. According to the Ottawa Risk Score, a woman with breast cancer would have a higher risk of thrombosis than a woman with lung cancer. A history of VTE does predict a higher risk for VTE. According to the Ottawa risk score, women are more at risk for cancer-associated thrombosis than men.</p>\r\n\r\n\r\n<h1>\r\n<a name=\"Heading320\"></a><strong>Content</strong></h1>\r\n<p><strong>&lt;&lt;level 1&gt;&gt; Educational Impact Challenge</strong></p>\r\n\r\n<p>The goal of this activity is to provide an update on new treatment strategies for patients with cancer at risk for thromboembolism.</p>\r\n\r\n<p>Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.</p>\r\n\r\n<p>&lt;&lt;Insert pre-assessment questions 1-4&gt;&gt;</p>\r\n\r\n<p><strong>"},{"articleID":"","componentNumber":2,"slidePath":"//_3","rawSlides":""}]